Home  »  Companies   »  Is Pacific Biosciences of California Inc. (PACB) a...

Is Pacific Biosciences of California Inc. (PACB) a Keeper?

Pacific Biosciences of California Inc. (NASDAQ:PACB) went down by -4.32% from its latest closing price compared to the recent 1-year high of $14.20. The company’s stock price has collected -9.82% of loss in the last five trading sessions. Barron’s reported on 10/26/22 that Pacific Bio Pushes Back at Illumina With New No-Compromise Gene Readers

Is It Worth Investing in Pacific Biosciences of California Inc. (NASDAQ :PACB) Right Now?

Plus, the 36-month beta value for PACB is at 1.62.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


PACB currently public float of 206.29M and currently shorts hold a 11.96% ratio of that float. Today, the average trading volume of PACB was 4.71M shares.

PACB’s Market Performance

PACB stocks went down by -9.82% for the week, with a monthly jump of 17.95% and a quarterly performance of 39.51%, while its annual performance rate touched 7.86%. The volatility ratio for the week stands at 7.39% while the volatility levels for the past 30 days are set at 8.24% for Pacific Biosciences of California Inc. The simple moving average for the period of the last 20 days is 13.05% for PACB stocks with a simple moving average of 54.93% for the last 200 days.

Analysts’ Opinion of PACB

Many brokerage firms have already submitted their reports for PACB stocks, with Cantor Fitzgerald repeating the rating for PACB by listing it as a “Neutral.” The predicted price for PACB in the upcoming period, according to Cantor Fitzgerald is $12 based on the research report published on January 20th of the current year 2023.

Scotiabank, on the other hand, stated in their research note that they expect to see PACB reach a price target of $12. The rating they have provided for PACB stocks is “Sector Outperform” according to the report published on January 05th, 2023.

Cantor Fitzgerald gave a rating of “Overweight” to PACB, setting the target price at $31 in the report published on January 21st of the previous year.

PACB Trading at 10.95% from the 50-Day Moving Average

After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.66% of loss for the given period.

Volatility was left at 8.24%, however, over the last 30 days, the volatility rate increased by 7.39%, as shares surge +19.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.98% upper at present.

During the last 5 trading sessions, PACB fell by -9.82%, which changed the moving average for the period of 200-days by +23.18% in comparison to the 20-day moving average, which settled at $9.68. In addition, Pacific Biosciences of California Inc. saw 32.52% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PACB starting from Van Oene Mark, who sale 26,722 shares at the price of $9.53 back on Jan 10. After this action, Van Oene Mark now owns 640,808 shares of Pacific Biosciences of California Inc., valued at $254,768 using the latest closing price.

HENRY CHRISTIAN O, the of Pacific Biosciences of California Inc., sale 45,000 shares at $10.84 during a trade that took place back on Dec 01, which means that HENRY CHRISTIAN O is holding 643,551 shares at $487,980 based on the most recent closing price.

Stock Fundamentals for PACB

Current profitability levels for the company are sitting at:

  • -136.51 for the present operating margin
  • +45.04 for the gross margin

The net margin for Pacific Biosciences of California Inc. stands at -138.85. Equity return is now at value -42.20, with -15.70 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 15.35.

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.


We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam